The UK and US have established a important bilateral deal that will guarantee zero levies on British drug products entering the US market.
The Terms of the Accord
As part of the deal, the UK has agreed to raise expenditure on medicines through the public health system. This move ensures that tariffs on these crucial exports will be held at zero for a timeframe of three years.
This agreement is in response to recent warnings to hike duties on patented drug products, with potential rates mentioned up to one hundred percent.
"This agreement with the Britain strengthens the international landscape for cutting-edge drugs and establishes much-needed fairness to transatlantic pharmaceutical trade," a statement said.
Trade Significance
Medicines constitute one of the the United Kingdom's largest export categories to the US, which is easily the primary buyer for major UK drugmakers.
Export figures show that in the one-year period prior to last September, the UK exported medicines worth billions to the US. This figure accounted for 17.4% of total UK exports in that timeframe.
"This guarantee protects work, stimulates funding and paves the way for the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Key NHS Changes
The pact includes several specific pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by 25%.
- Increased NHS Spending: There is a target to double overall NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to stay within budget will be restricted at 15%. In the past, refunds were more than 20%.
Recent Tensions
The deal comes amid a long-running tension between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
This friction were exacerbated by claims that American patients were charged several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or abandoned, while major expansions have been directed toward US facilities.
One official acknowledged that the NHS needed to spend more on drugs, noting that its spending on drugs had decreased as a share of its overall budget over the last ten years.
